Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: A pilot study

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Engbersen, Richard ^a,d   Riksen, Niels P ^a,b   Mol, Marc J ^e   Bravenboer, Bert ^f   Boerman, Otto C ^c   Meijer, Patrick ^a   Oyen, Wim J G ^c   Tack, Cees ^b   Rongen, Gerard A ^a,b   Smits, Paul ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b General Internal Medicine   (Netherlands)

^c Nuclear Medicine   (Netherlands)

^d SLINGELAND HOSPITAL   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f CATHARINA HOSPITAL   (Netherlands)

Author keywords

Annexin A5; Hyperglycemia; Ischemia reperfusion injury; Ischemic preconditioning; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPOCORTIN 5; TECHNETIUM 99M;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORONARY REPERFUSION; CORONARY VASCULAR RESISTANCE; CROSSOVER PROCEDURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC PRECONDITIONING; MALE; OUTCOME ASSESSMENT; REPERFUSION INJURY; SCINTIGRAPHY;

ADULT; ANALYSIS OF VARIANCE; ANNEXIN A5; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FOREARM; HUMANS; HYPERINSULINISM; INSULIN; ISCHEMIC PRECONDITIONING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; ORGANOTECHNETIUM COMPOUNDS; PERFUSION IMAGING; PILOT PROJECTS; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW; REPERFUSION INJURY; TIME FACTORS; YOUNG ADULT;

EID: 84867192742     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-124     Document Type: Article

References (40)

1. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care 2006, 29:2528-2538. 10.2337/dc06-1161, 17065698.
2. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004, 109:476-480. 10.1161/01.CIR.0000109693.64957.20, 14732749.
3. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA 2007, 298:765-775. 10.1001/jama.298.7.765, 17699010.
4. Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, Guyton RA. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999, 67:1045-1052. 10.1016/S0003-4975(99)00143-5, 10320249.
5. van Straten AH, Soliman Hamad MA, van Zundert AA, Martens EJ, Schonberger JP, ter Woorst JF, de Wolf AM. Diabetes and survival after coronary artery bypass grafting: comparison with an age- and sex-matched population. Eur J Cardiothorac Surg 2010, 37:1068-1074. 10.1016/j.ejcts.2009.11.042, 20036136.
6. Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011, 378:140-146. 10.1016/S0140-6736(11)60471-6, 21705065.
7. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136. 10.1161/01.CIR.74.5.1124, 3769170.
8. Riksen NP, Smits P, Rongen GA. Ischaemic preconditioning: from molecular characterization to clinical application. Part II. Neth J Med 2004, 62:409-423.
9. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007, 59:418-458. 10.1124/pr.107.06002, 18048761.
10. Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ. The diabetic heart: too sweet for its own good?. Cardiol Res Pract 2012, 2012:845698. 3296224, 22462028.
11. Rongen GA, Oyen WJG, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation 2005, 111:173-178. 10.1161/01.CIR.0000151612.02223.F2, 15623546.
12. Riksen NP, Zhou Z, Oyen WJ, Jaspers R, Ramakers BP, Brouwer RM, Boerman OC, Steinmetz N, Smits P, Rongen GA. Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol 2006, 48:700-707. 10.1016/j.jacc.2006.04.083, 16904537.
13. Riksen NP, Franke B, Oyen WJ, Borm GF, van den Broek P, Boerman OC, Smits P, Rongen GA. Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. Eur Heart J 2007, 28:1085-1091. 10.1093/eurheartj/ehm032, 17376785.
14. Meijer P, Oyen WJ, Dekker D, Van den Broek PH, Wouters CW, Boerman OC, Scheffer GJ, Smits P, Rongen GA. Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol 2009, 29:963-968. 10.1161/ATVBAHA.108.179622, 19359665.
15. Wouters CW, Meijer P, Janssen CI, Frederix GW, Oyen WJ, Boerman OC, Smits P, Rongen GA. Atorvastatin does not affect ischaemia-induced phosphatidylserine exposition in humans in-vivo. J Atheroscler Thromb 2012, 19:285-291. 10.5551/jat.10983, 22146238.
16. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994, 84:1415-1420.
17. Schreiber-Deturmeny E, Bruguerolle B. Simultaneous high-performance liquid chromatographic determination of caffeine and theophylline for routine drug monitoring in human plasma. J Chromatogr B Biomed Appl 1996, 677:305-312. 10.1016/0378-4347(95)00383-5, 8704934.
18. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135. 10.1056/NEJMra071667, 17855673.
19. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di SC, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007, 370:575-579. 10.1016/S0140-6736(07)61296-3, 17707752.
20. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, Stone GW. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol 2007, 100:206-210. 10.1016/j.amjcard.2007.02.080, 17631071.
21. Alegria JR, Miller TD, Gibbons RJ, Yi QL, Yusuf S. Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am Heart J 2007, 154:743-750. 10.1016/j.ahj.2007.06.020, 17893003.
22. Rodrigues B, Rosa KT, Medeiros A, Schaan BD, Brum PC, De AK, Irigoyen MC. Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. Cardiovasc Diabetol 2011, 10:26. 10.1186/1475-2840-10-26, 3084163, 21470409.
23. Paulson DJ. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 1997, 34:104-112. 10.1016/S0008-6363(97)00018-7, 9217879.
24. Balakumar P, Sharma NK. Healing the diabetic heart: does myocardial preconditioning work?. Cell Signal 2012, 24:53-59. 10.1016/j.cellsig.2011.09.007, 21945408.
25. Feuvray D, Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res 1997, 34:113-120. 10.1016/S0008-6363(97)00037-0, 9217880.
26. Miki T, Itoh T, Sunaga D, Miura T. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 2012, 11:67. 10.1186/1475-2840-11-67, 3461466, 22694800.
27. Van der Mieren G, Nevelsteen I, Vanderper A, Oosterlinck W, Flameng W, Herijgers P. Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury. Cardiovasc Diabetol 2012, 11:89. 10.1186/1475-2840-11-89, 3444392, 22853195.
28. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000, 278:H1218-H1224.
29. del Valle HF, Lascano EC, Negroni JA, Crottogini AJ. Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP channel dysfunction. Mol Cell Biochem 2003, 249:21-30. 10.1023/A:1024797530152, 12956394.
30. Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol 1998, 275:H721-H725.
31. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005, 54:2360-2364. 10.2337/diabetes.54.8.2360, 16046302.
32. Ghosh S, Standen NB, Galinianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol 2001, 37:711-718. 10.1016/S0735-1097(00)01161-X, 11693741.
33. Hassouna A, Loubani M, Matata BM, Fowler A, Standen NB, Galinanes M. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc Res 2006, 69:450-458. 10.1016/j.cardiores.2005.11.004, 16330008.
34. Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM. Preconditioning the diabetic human myocardium. J Cell Mol Med 2010, 14:1740-1746.
35. Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 2000, 32:757-764. 10.1006/jmcc.2000.1118, 10775481.
36. Melin J, Hellberg O, Larsson E, Zezina L, Fellstrom BC. Protective effect of insulin on ischemic renal injury in diabetes mellitus. Kidney Int 2002, 61:1383-1392. 10.1046/j.1523-1755.2002.00284.x, 11918745.
37. Sack MN, Yellon DM. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 2003, 41:1404-1407. 10.1016/S0735-1097(03)00164-5, 12706939.
38. Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, Warltier DC. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 2001, 280:H1744-H1750.
39. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Umemura T, Nakamura S, Yoshida M. Effect of acute hyperglycemia on the ischemic preconditioning effect of prodromal angina pectoris in patients with a first anterior wall acute myocardial infarction. Am J Cardiol 2003, 92:288-291. 10.1016/S0002-9149(03)00627-1, 12888134.
40. Wade AO, Cordingley JJ. Glycaemic control in critically ill patients with cardiovascular disease. Curr Opin Crit Care 2006, 12:437-443. 10.1097/01.ccx.0000244123.39247.b9, 16943722.